PARP1 and hepatocellular carcinoma: Based on the results of these analyses, we have concluded that a novel path in which momelotinib induces DNA damage and sensitizes viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness via IFNGR-JAK2-STAT1-PARP1 axis.